Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study

Details

Serval ID
serval:BIB_6546628A5894
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study
Journal
Atherosclerosis Plus
Author(s)
Ray Kausik K., Haq Inaam, Bilitou Aikaterini, Aguiar Carlos, Arca Marcello, Connolly Derek L., Eriksson Mats, Ferrières Jean, Hildebrandt Per, Laufs Ulrich, Mostaza Jose M., Nanchen David, Rietzschel Ernst, Strandberg Timo, Toplak Hermann, Visseren Frank L.J., Catapano Alberico L.
ISSN
2667-0895
Publication state
Published
Issued date
09/2021
Volume
43
Pages
24-30
Language
english
Notes
L2014119211
2021-12-10
Abstract
Background and aims: Clinical practice before 2019 suggests a substantial proportion of high and very high CV risk patients taking lipid-lowering therapy (LLT) would not achieve the new LDL-C goals recommended in the 2019 ESC/EAS guidelines (<70 and < 55 mg/dL, respectively). To what extent practice has changed since the last ESC/EAS guideline update is uncertain, and quantification of remaining implementation gaps may inform health policy. Methods: The SANTORINI study is a multinational, multicentre, prospective, observational, non-interventional study documenting patient data at baseline (enrolment) and at 12-month follow-up. The study recruited 9606 patients ≥18 years of age with high and very high CV risk (as assigned by the investigators) requiring LLT, with no formal patient or comparator groups. The primary objective is to document, in the real-world setting, the effectiveness of current treatment modalities in managing plasma levels of LDL-C in high- and very high-risk patients requiring LLT. Key secondary effectiveness objectives include documenting the relationship between LLT and levels of other plasma lipids, high-sensitivity C-reactive protein (hsCRP) and overall predicted CV risk over one year. Health economics and patient-relevant parameters will also be assessed. Conclusions: The SANTORINI study, which commenced after the 2019 ESC/EAS guidelines were published, is ideally placed to provide important contemporary insights into the evolving management of LLT in Europe and highlight factors contributing to the low levels of LDL-C goal achievement among high and very high CV risk patients. It is hoped the findings will help enhance patient management and reduce the burden of ASCVD in Europe.
Keywords
achievement, adult, article, cardiovascular risk, controlled study, coronary artery atherosclerosis, Europe, female, follow up, health economics, high risk patient, human, human tissue, lipid blood level, major clinical study, male, multicenter study, patient care, patient coding, practice guideline, prevention, prospective study, risk assessment, C reactive protein, endogenous compound, low density lipoprotein cholesterol
Open Access
Yes
Create date
23/12/2021 12:55
Last modification date
02/04/2022 6:35
Usage data